Skip to main content
. 2020 Mar 27;9(11):3656–3667. doi: 10.1002/cam4.2991

Figure 5.

Figure 5

Cases showing delayed response to trabectedin. ▼, trabectedin dose. A, Case 1: male aged 40 y after systemic therapy with doxorubicin, ifosfamide, and cyclophosphamide. After the evaluation of the clinical trial outcome, trabectedin treatment was continued as a form of ordinary clinical care. B, Case 2: female aged 70 y after systemic therapy with doxorubicin